FGFR2 and intrahepatic cholangiocarcinoma: Through these impressive efforts, actionable driver mutations are detected in up to 40% of ICC, including 15% with oncogenic translocations in Fibroblast Growth Factor Receptor 2 (FGFR2) that promote proliferation, cell migration, and survival14.